

IBC Meeting Minutes

Cleveland Clinic Florida Research and Innovation Center

Date: July 16 th , 2026	Location: Zoom
IBC Member Attendance: ☒ McDonald, Christine (IBC Chair) ☒ Li, Kun ☒ Such, Kimberly ☒ Champer, Dylan (Biosafety Officer) ☒ Hajjar, Adeline ☒ Judd, Leslie ☒ Tavakoli, Sara ☐ O'Connor, Christine ☒ Doud, Melissa ☒ Stolley, Michael <i>Guests: Amanda Dragan *, Anna Rietsch *, Anthony Santilli*, Nikki Meyer*, Abby Bifano</i> <i>*Cleveland Clinic Main Campus</i>	
Call To Order: 2:30 pm	Adjourn: 2:48 pm

I. Review of June 18th, 2026 Meeting Minutes

Committee Comments: None			
Motion: Approved	For: 8	Against: 0	Abstain: 1

II. Administrative Business

- a. Committee presented with Subcommittee Review items, personnel additions, and updates to programmatic SOPs.

III. Non-Clinical Research:

a. Amendments:

Basic Research Amendment # 1	Protocol ID: FLIBC021	PI: Sautto	Biosafety Level: BSL-1, BSL-2+, ABSL-2	NIH Cat.: III-E, III-D-1-a, III-D-2-a, III-D-3-a, III-D-4-b
Project Titles: Influenza and hepatitis C virus neutralization				
Associated Grant Numbers: Non-NIH Funding				
Summary of Approved Items:				

Propagation and generation of Influenza A & B viral strains and recombinant Hepatitis C Virus, virus like particles / pseudoparticles; Transduction of tissue culture cells; Generation of phagemid and retroviral particles, transduction of cells in-vitro, administration of Influenza A & B viral strains, plasmid DNA, <i>in vivo</i> ; Generation and propagation of Measles virus; Generation of Nipah pseudovirus; Recombinant and Non-Recombinant Respiratory syncytial virus and human metapneumovirus for in vitro and <i>in vivo</i> experiments; Propagation of SARS-CoV-2, <i>in vivo</i> administration of SARS-CoV-2, human-derived materials.					
Requested Additions/Changes: Addition of H5/PR8 influenza A strains, Addition of plasmids for the expression of the soluble surface recombinant proteins for Andes, Nombre, Hantaan and Dobrava-Belgrade viruses, recombinant Measles and Mumps virus expressing HCV/E1-E2 glycoproteins, ANDV pseudoparticle and VLP neutralization assay.					
Function/Nature of Recombinant Genes to be Expressed: ☐ N/A ☐ Oncogene ☐ Tumor Suppressor Gene ☐ Structural ☒ Signaling ☐ Antimicrobial ☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Other					
Species of Recombinant Genes to be Expressed: ☐ N/A ☐ Human ☐ Murine ☐ Rat ☐ Bacterial ☐ Viral ☒ Other					
Risk Assessment Discussion: ☒ Yes ☐ No			Facilities, Procedures, and Safety Practices Reviewed (Y/N): ☒ Yes ☐ No		
Committee Comments: - Update form to include details for new in vivo procedure - Administrative edits					
PI/Supervisor Training (Y/N): ☒ Yes ☐ No			Handler Training (Y/N): ☒ Yes ☐ No		
Motion: Approved with Administrative Revisions	For: 9	Against: 0	Abstain: 0	Recuse: 0	Not Present: 0